Published in Nature on January 17, 2008
Frequent pathway mutations of splicing machinery in myelodysplasia. Nature (2011) 11.44
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet (2009) 8.03
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood (2009) 4.64
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Ribosomopathies: human disorders of ribosome dysfunction. Blood (2010) 4.43
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene (2009) 4.10
Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med (2009) 4.03
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet (2011) 4.02
Signaling to p53: ribosomal proteins find their way. Cancer Cell (2009) 3.84
Long non-coding RNAs and cancer: a new frontier of translational research? Oncogene (2012) 3.83
How common are extraribosomal functions of ribosomal proteins? Mol Cell (2009) 3.51
Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev (2010) 3.24
Abnormalities of the large ribosomal subunit protein, Rpl35a, in Diamond-Blackfan anemia. Blood (2008) 3.05
Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol (2009) 2.97
SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature (2012) 2.96
A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med (2009) 2.89
Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood (2010) 2.84
Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol (2011) 2.69
Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood (2012) 2.51
Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol (2009) 2.48
Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nat Genet (2015) 2.43
High-throughput Phenotyping of Lung Cancer Somatic Mutations. Cancer Cell (2016) 2.31
Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med (2014) 2.11
Comprehensive molecular structure of the eukaryotic ribosome. Structure (2009) 2.04
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes Dev (2011) 1.89
Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. Blood (2011) 1.84
A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A (2009) 1.83
Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol (2008) 1.83
Crosstalk between c-Myc and ribosome in ribosomal biogenesis and cancer. J Cell Biochem (2008) 1.77
When ribosomes go bad: diseases of ribosome biogenesis. Mol Biosyst (2010) 1.76
TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet (2009) 1.75
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood (2011) 1.74
Cytogenetic features in myelodysplastic syndromes. Ann Hematol (2008) 1.74
Translational control in cancer etiology. Cold Spring Harb Perspect Biol (2013) 1.71
Principles and strategies for developing network models in cancer. Cell (2011) 1.65
Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia. Hum Mutat (2012) 1.64
Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. Leukemia (2009) 1.63
Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. Proc Natl Acad Sci U S A (2008) 1.63
Diamond-Blackfan anemia: genotype-phenotype correlations in Italian patients with RPL5 and RPL11 mutations. Haematologica (2009) 1.63
Functional dichotomy of ribosomal proteins during the synthesis of mammalian 40S ribosomal subunits. J Cell Biol (2010) 1.58
Integrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis. PLoS One (2009) 1.53
Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am (2009) 1.52
Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci U S A (2008) 1.49
Mutant U2AF1 Expression Alters Hematopoiesis and Pre-mRNA Splicing In Vivo. Cancer Cell (2015) 1.47
HTLV-1 integration into transcriptionally active genomic regions is associated with proviral expression and with HAM/TSP. PLoS Pathog (2008) 1.45
Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk. Cancer Cell (2011) 1.44
Suprainduction of p53 by disruption of 40S and 60S ribosome biogenesis leads to the activation of a novel G2/M checkpoint. Genes Dev (2012) 1.44
The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Mol Cell Biol (2009) 1.40
Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol (2008) 1.39
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature (2017) 1.39
The cancerous translation apparatus. Curr Opin Genet Dev (2011) 1.38
Loss of ribosomal protein L11 affects zebrafish embryonic development through a p53-dependent apoptotic response. PLoS One (2009) 1.36
The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood (2010) 1.33
Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood (2012) 1.33
Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature (2015) 1.32
Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood (2014) 1.29
Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood (2012) 1.29
Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS. Cancer Cell (2014) 1.28
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes. Nat Rev Cancer (2012) 1.27
Many ribosomal protein mutations are associated with growth impairment and tumor predisposition in zebrafish. Dev Dyn (2009) 1.27
How I treat Diamond-Blackfan anemia. Blood (2010) 1.27
A genetic screen in zebrafish defines a hierarchical network of pathways required for hematopoietic stem cell emergence. Blood (2009) 1.27
A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet (2008) 1.26
Diamond Blackfan anemia 2008-2009: broadening the scope of ribosome biogenesis disorders. Curr Opin Pediatr (2010) 1.22
Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood (2010) 1.21
Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene (2012) 1.19
Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem (2008) 1.18
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer (2008) 1.18
Integrative genomic analysis of human ribosomal DNA. Nucleic Acids Res (2011) 1.18
Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood (2011) 1.17
The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood (2012) 1.16
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood (2008) 1.16
Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion. Oncogene (2012) 1.16
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes. J Clin Oncol (2010) 1.14
Nucleolar stress with and without p53. Nucleus (2014) 1.13
The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle (2009) 1.13
Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood (2009) 1.11
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course. Blood (2009) 1.11
Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. Dev Cell (2013) 1.11
Ribosomal protein L11 mutation in zebrafish leads to haematopoietic and metabolic defects. Br J Haematol (2010) 1.10
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res (2010) 1.10
The other lives of ribosomal proteins. Hum Genomics (2010) 1.10
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res (2009) 1.09
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact (2009) 1.08
Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood (2011) 1.08
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
Mutations in the ribosomal protein genes in Japanese patients with Diamond-Blackfan anemia. Haematologica (2010) 1.07
Untangling the phenotypic heterogeneity of Diamond Blackfan anemia. Semin Hematol (2011) 1.06
Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet (2010) 1.06
Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome. Blood (2011) 1.05
Molecular dissection of the 5q deletion in myelodysplastic syndrome. Semin Oncol (2011) 1.05
Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability. Oncotarget (2014) 1.05
Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat Biotechnol (2015) 1.04
The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome. Mol Cancer Res (2013) 1.04
Ribosome defects in disorders of erythropoiesis. Int J Hematol (2011) 1.03
Scission of the p53-MDM2 Loop by Ribosomal Proteins. Genes Cancer (2012) 1.00
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A (1971) 31.05
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68
Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell (2006) 12.72
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet (1999) 6.23
Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood (2002) 4.72
Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol (2004) 3.99
Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet (2004) 3.84
Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. Am J Hum Genet (2006) 3.17
Myelodysplasia. N Engl J Med (1999) 2.94
Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol (2001) 2.72
Identification of a human heme exporter that is essential for erythropoiesis. Cell (2004) 2.66
Roles of eukaryotic ribosomal proteins in maturation and transport of pre-18S rRNA and ribosome function. Mol Cell (2005) 2.65
Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature (1974) 2.56
Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood (2002) 2.50
Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood (1995) 2.42
Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood (2007) 2.30
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med (2006) 2.23
Human RPS19, the gene mutated in Diamond-Blackfan anemia, encodes a ribosomal protein required for the maturation of 40S ribosomal subunits. Blood (2006) 2.22
Ribosomes and marrow failure: coincidental association or molecular paradigm? Blood (2006) 2.02
An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med (2008) 1.97
Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res (2006) 1.83
Cancer biology. A matter of dosage. Science (2002) 1.59
Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood (2000) 1.26
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
GenePattern 2.0. Nat Genet (2006) 29.07
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet (2001) 13.79
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
lincRNAs act in the circuitry controlling pluripotency and differentiation. Nature (2011) 11.31
Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood (2004) 11.07
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat Genet (2004) 10.92
Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci U S A (2004) 10.47
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
A mechanism of cyclin D1 action encoded in the patterns of gene expression in human cancer. Cell (2003) 9.81
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med (2006) 8.16
Molecular signatures database (MSigDB) 3.0. Bioinformatics (2011) 8.08
Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res (2003) 8.06
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med (2006) 7.95
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol Cell Biol (2002) 7.44
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A (2012) 7.14
Selective killing of cancer cells by a small molecule targeting the stress response to ROS. Nature (2011) 7.03
Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell (2011) 7.03
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics (2007) 6.63
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses. Science (2009) 6.07
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med (2011) 5.24
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev (2009) 5.21
Scoring diverse cellular morphologies in image-based screens with iterative feedback and machine learning. Proc Natl Acad Sci U S A (2009) 5.15
A physical and regulatory map of host-influenza interactions reveals pathways in H1N1 infection. Cell (2009) 4.98
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Automated high-dimensional flow cytometric data analysis. Proc Natl Acad Sci U S A (2009) 4.91
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Conserved pathways within bacteria and yeast as revealed by global protein network alignment. Proc Natl Acad Sci U S A (2003) 4.68
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol (2010) 4.48
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell (2006) 3.93
Myelodysplastic syndromes: incidence and survival in the United States. Cancer (2007) 3.89
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Dev Cell (2008) 3.84